SLC5A2 and diabetes mellitus: Additional data from ongoing trials in diabetes mellitus will further clarify the impact of SGLT2 inhibitors on this major cause of mortality and morbidity25,26 and confirm or refute hypotheses raised by the CANVAS and EMPA-REG OUTCOME trial findings.